Kyverna Therapeutics, Inc. - 8-K Filing

Kyverna Therapeutics completes BLA submission for miv-cel in Stiff Person Syndrome and reports Q3 2026 net loss of $41.9 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 12, 2026, 13:01 UTC

Tickers: $KYTX

Read the full article at SEC EDGAR

More Regulatory news

FILANA THERAPEUTICS, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 13:18 UTC
RUM Group Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:17 UTC
Theriva Biologics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SeaStar Medical Holding Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
Avalyn Pharma Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SES AI Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
Data443 Risk Mitigation, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
TRUSTMARK CORP - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SUBURBAN PROPANE PARTNERS LP - 8-K Filing SEC EDGAR · November 12, 2026, 13:14 UTC
MeiraGTx Holdings plc - 10-Q Filing SEC EDGAR · November 12, 2026, 13:13 UTC